Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

October 1, 2012

Primary Completion Date

December 12, 2018

Study Completion Date

December 12, 2018

Conditions
Metastatic Prostate Cancer
Interventions
BIOLOGICAL

Indoximod

Given twice daily (1200 mg total) by mouth for 6 months.

BIOLOGICAL

Sipuleucel-T

Sipuleucel-T will be administered as standard of care. Given by infusion over 60 minutes at Week 0, 2 and 4. Patients will undergo leukapheresis at weeks 0, 2, and 4 with sipuleucel-T infused 3 days later (i.e. Monday/Thursday; Tuesday/Friday).

OTHER

Placebo

Given in same manner as Indoximod; 1200 mg per day by mouth.

Trial Locations (4)

10065

New York Presbyterian/Weill Cornell Medical Center, New York

17033

Penn State Milton S. Hershey Medical Center, Hershey

55455

Masonic Cancer Center, University of Minnesota, Minneapolis

60612

University of Illinois Medical Center, Chicago

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT01560923 - Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter